Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:4:271-8.
doi: 10.2147/IJWH.S31740. Epub 2012 Jul 12.

Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding

Radoslaw Wasiak  1 , Anna Filonenko, David J Vanness, Kim U Wittrup-Jensen, Donald E Stull, Steven Siak, Ian Fraser
Affiliations

Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding

Radoslaw Wasiak et al. Int J Womens Health. 2012.

Abstract

Background: The purpose of this study was to quantify the impact of estradiol-valerate/dienogest (E(2)V/DNG; Qlaira(®)/Natazia(®)) on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding.

Methods: Women aged 18-54 years with a confirmed diagnosis of heavy menstrual bleeding and no recognizable pathology were recruited across nine European countries (the Czech Republic, Finland, Germany, Hungary, The Netherlands, Poland, Sweden, UK, and Ukraine) and Australia. The women were randomized to receive either E(2)V/DNG (n = 149) or placebo (n = 82) for seven treatment cycles (196 days). The outcomes assessed included work productivity (ie, productivity while at work) and activities of daily living, measured on a Likert scale from 0 to 10 (with higher values denoting higher impairment levels) at baseline and at the end of the third and seventh cycles (days 84 and 196). The equivalent monetary value associated with the changes in work productivity and activities of daily living was also calculated.

Results: Across all the countries, greater improvements from baseline to the end of treatment were observed with E(2)V/DNG treatment than placebo in work productivity (46.0% versus 15.1%) and activities of daily living (55.6% versus 30.8%). In 2008, savings associated with improvements in work productivity and activities of daily living due to E(2)V/DNG treatment (net of placebo improvement) were estimated to be between US$22-62 and US$18-56 per month (in purchasing power parity of US$), respectively.

Conclusion: E(2)V/DNG has a consistent positive impact on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. These improvements were associated with a reduction in monetary burden of heavy menstrual bleeding compared with the placebo group, consistent with the response to treatment observed.

Keywords: activities of daily living; dienogest; estradiol valerate; heavy menstrual bleeding; work productivity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Work productivity impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire. Note: Value of “0” indicate no impairment due to heavy menstrual bleeding and value of “10” indicate complete work productivity impairment (ie, prevents undertaking any work). Abbreviation: EOT, end of treatment; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.
Figure 2
Figure 2
Activities of daily living impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire. Note: Value of “0” indicate no impairment due to HMB and value of “10” indicate complete impairment of activities of daily living (ie, prevents undertaking any usual activities). Abbreviations: EOT, end of treatment; E2V/DNG, estradiol-valerate/dienogest; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.
Figure 3
Figure 3
Reduction in work productivity and activities of daily living impairment across all countries (baseline to end of treatment) by treatment group (negative values indicate improvement). Abbreviation: E2V/DNG, estradiol-valerate/dienogest.
See this image and copyright information in PMC

References

    1. National Institute for Clinical Excellence. Heavy Menstrual Bleeding Costing report: Implementing NICE guidance in England. 2007. [Accessed October 9, 2009]. Available from: http://www.nice.org.uk/page.aspx?o=CG044CostReport.
    1. National Collaborating Centre for Women’s and Children’s Health. Heavy Menstrual Bleeding. Clinical Guideline. National Institute for Health and Clinical Excellence. London, UK: RCOG Press; 2007.
    1. National Institute for Clinical Excellence. Technology Appraisal 78. London, UK: National Institute for Clinical Excellence; 2004. Fluid-filled Thermal Balloon and Microwave Endometrial Ablation Techniques for Heavy Menstrual Bleeding.
    1. Fraser IS, Langham S. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol. 2009;4(2):179–189.
    1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194. - PubMed